In the present study, the detection rate of EML4-ALK fusion gene increased from 1.0% (2/202 patients with unselected lung cancer) in the test set to 5.1% (8/158 patients with EGFR and KRAS mutation-negative adenocarcinoma) in the validation set. This evidence concerns the gene EGFR and lung carcinoma.